From Specialty Pharmacy News - Following last month’s FDA approval of the first drug to take the abbreviated 351(k) biosimilar approval pathway, some of the unknown issues around these drugs have been addressed. Two weeks after the approval of Sandoz Inc.’s Zarxio (filgrastim-sndz) on March 6 (SPN 3/15, p. 1) came a decision in the lawsuit (Amgen Inc. et al v. Sandoz Inc. et al, Case No. 3:14-cv-04741-RS) brought by Amgen Inc., manufacturer of Neupogen (filgrastim), the reference drug for Zarxio. Read more
From Drug Benefit News - In a move that surprised many industry analysts, UnitedHealth Group on March 30 unveiled plans to acquire stand-alone PBM Catamaran Corp. and merge it with the health plan operator’s PBM unit, OptumRx. The combined firm will process approximately 1 billion prescriptions per year, securing OptumRx’s spot as the third-largest PBM. Under the agreement, UnitedHealth Group will acquire Catamaran’s outstanding common stock for $61.50 per share in cash. Read more
From Drug Benefit News - According to the new Drug Trend Report from Express Scripts Holding Co., two primary contributors to drug trend last year were hepatitis C therapies and compounded medications. The PBM estimates that those two factors combined drove more than half of a 13.1% increase in overall spending; setting those classes aside, 2014 drug trend (defined as the year-over-year increase in per capita drug spending) was 6.4%. As forecasted last year, specialty trend… Read more
Check out all of the benefits, sample issues & more!